AVBP
Arrivent Biopharma
$30.16
−$1.57 (−4.95%)Jul 27, 2026
Key metrics
The numbers that frame AVBP today
- Market cap
- $1.40B
- P/E (TTM)
- -9.7
- EV / FCF
- -10.0
- ROIC
- -68%
- Div yield
- 0%
- Debt / equity
- 0.0
- 52wk Low
- $16.10
- 52wk High
- $35.83
Growth
Revenue and earnings trend for AVBP
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about AVBP
Is Arrivent Biopharma a good buy?
Hold. Arrivent Biopharma has excellent momentum, but poor quality makes the setup mixed. Growth looks excellent, which supports the long-term business case. We think Arrivent Biopharma is selling at a very high price.
What is the market capitalization of AVBP?
Arrivent Biopharma's market capitalization is $1.40B.
What is the P/E ratio for AVBP stock?
Arrivent Biopharma's current P/E ratio is -9.7.
What is the 52-week high for AVBP stock?
The 52-week high for Arrivent Biopharma is $35.83. The current close of $30.16 is 15.8% below that high.
What is the 52-week low for AVBP stock?
The 52-week low for Arrivent Biopharma is $16.10. The current close of $30.16 is 87.3% above that low.
Does AVBP stock pay dividends?
Arrivent Biopharma does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for AVBP?
Arrivent Biopharma's Debt / Equity ratio is 0.